A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

Haematologica. 2018 Sep;103(9):e416-e418. doi: 10.3324/haematol.2018.187617. Epub 2018 Apr 5.

Authors

Paolo Strati¹, Dai Chihara², Yasuhiro Oki³, Luis E Fayad³, Nathan Fowler³, Loretta Nastoupil³, Jorge E Romaguera³, Felipe Samaniego³, Naveen Garg⁴, Lei Feng⁵, Emily T Wesson³, Charnelle E Ruben³, Mildred D Stafford³, Yago Nieto⁶, Issa F Khouri⁶, Chitra Hosing⁶, Sandra B Horowitz³, Rammurti T- Kamble⁷, Michelle A Fanale⁸

Affiliations

¹ Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
² Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
³ Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Hematology-Oncology, Baylor College of Medicine and Houston Methodist Hospital, TX, USA.
⁸ Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA mfanale@mdanderson.org.

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Drug Resistance
Etoposide / administration & dosage
Humans
Ifosfamide / administration & dosage
Lymphoma, T-Cell, Peripheral / drug therapy*
Lymphoma, T-Cell, Peripheral / mortality
Lymphoma, T-Cell, Peripheral / pathology*
Recurrence
Retreatment
Treatment Outcome

Substances

Etoposide
Carboplatin
Ifosfamide

Associated data

ClinicalTrials.gov/NCT01590732

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States